Eli Lilly vs Novo Nordisk: Revenue Comparison
Eli Lilly (LLY) and Novo Nordisk (NVO) are peers in GLP-1. Eli Lilly reported revenue of $19.8B as of Q1 2026, compared with $96.8B for Novo Nordisk. Novo Nordisk leads on revenue.
Eli Lilly's gross margin is 81.9% versus 86.0% for Novo Nordisk. Eli Lilly's net margin is 37.4% versus 50.1% for Novo Nordisk.
Revenue Comparison
Chart: Revenue Comparison. Values in USD_BILLIONS. In Q1 2026: Eli Lilly 19.799, Novo Nordisk 96.823.
Latest Quarter Comparison
Table: Latest Quarter Comparison. 15 rows across Metric, Eli Lilly, Novo Nordisk.| Metric | Eli Lilly | Novo Nordisk |
|---|---|---|
| Market Cap | - | - |
| Revenue | $19.80B | $96.82B |
| Cost of Revenue | $3.58B | $13.60B |
| Gross Profit | $16.22B | $83.22B |
| Operating Income | $8.85B | $59.62B |
| Net Income | $7.40B | $48.56B |
| R&D Expense | $3.51B | $10.28B |
| Earnings Per Share | $8.26 | $10.91 |
| Gross Margin | 81.9% | 86.0% |
| Operating Margin | 44.7% | 61.6% |
| Net Profit Margin | 37.4% | 50.1% |
| Free Cash Flow | $3.01B | $12.04B |
| Cumulative Free Cash Flow | $101.90B | $654.97B |
| Operating Cash Flow | $5.33B | $24.08B |
| Cash & Equivalents | $5.14B | $21.13B |